CUPID.BOCUPID.BOBSE
Loading
Cupid Limited is an India-based manufacturer and exporter of male latex condoms and water-based lubricants, operating manufacturing facilities in Maharashtra with annual capacity exceeding 1.5 billion condoms. The company serves both B2B institutional markets (government tenders, NGOs, social marketing organizations) and B2C branded segments across 100+ countries, with significant exposure to emerging markets in Africa, Latin America, and Asia. Recent 516% one-year return reflects speculative momentum rather than fundamental transformation, with valuation multiples (39x P/S, 96x EV/EBITDA) disconnected from 5.6% revenue growth and deteriorating cash generation.
Cupid operates a high-margin manufacturing model with 75% gross margins driven by vertical integration in latex processing, automated production lines, and economies of scale at 1.5B+ unit capacity. Revenue comes from winning multi-year government tenders (typically 3-5 year contracts with volumes locked in), where price competitiveness and WHO/UNFPA pre-qualification status create barriers to entry. The B2C segment generates higher per-unit margins but requires marketing investment. Pricing power is limited in institutional segment due to tender-based procurement but stronger in branded retail. Operating leverage is moderate - fixed costs in manufacturing infrastructure are offset by variable raw material (natural rubber latex) and labor costs.
Major government tender wins from India's National AIDS Control Organization, African health ministries, or UNFPA procurement programs (contracts often $10-50M+ over multi-year periods)
Natural rubber latex price volatility - raw material represents 20-25% of COGS, with prices tied to Southeast Asian plantation output and global demand
Regulatory approvals and WHO pre-qualification status for new markets, particularly high-volume African and Latin American tenders
Retail brand penetration in India's growing sexual wellness market (estimated 15-20% annual growth) and e-commerce channel expansion
Currency movements in key export markets - USD/INR exchange rate affects competitiveness in dollar-denominated tenders
Commoditization of institutional condom market with intense price competition from Chinese and Thai manufacturers who benefit from lower labor costs and proximity to latex sources
Shift in public health funding priorities away from HIV/AIDS prevention programs toward other diseases, reducing government tender volumes
Regulatory changes in key markets requiring local manufacturing content, potentially excluding imports from India-based facilities
Dominant global players (Reckitt Benckiser's Durex, Church & Dwight's Trojan) have 10-20x revenue scale, stronger brand equity, and ability to outbid on large tenders
Chinese manufacturers (Guilin Latex, Karex Malaysia) offer 15-25% lower pricing in institutional segment due to cost advantages
Direct-to-consumer sexual wellness startups disrupting traditional retail channels with subscription models and digital marketing
Negative operating cash flow of -$0.1B and negative free cash flow of -$0.3B despite 22.6% net margin indicates working capital strain or accounting quality concerns requiring investigation
Extreme valuation multiples (39x P/S, 96x EV/EBITDA, 30x P/B) create significant downside risk if growth disappoints or sentiment shifts - current pricing implies 30-40% annual growth for 5+ years
Receivables concentration risk with government customers who may delay payments 6-12 months, particularly in fiscally constrained African nations
low - Contraceptive demand is relatively inelastic and driven by public health priorities rather than discretionary spending. Government procurement programs (60-70% of revenue) are funded through multi-year health budgets and international aid, insulating revenue from GDP fluctuations. However, branded consumer segment shows moderate sensitivity to disposable income growth in emerging markets.
Minimal direct impact given 0.07 debt/equity ratio and negligible interest expense. However, rising rates in developed markets can reduce international aid budgets and delay government tender releases in emerging economies. Valuation multiple compression is significant risk given extreme 96x EV/EBITDA - higher discount rates make growth stocks less attractive, particularly relevant given recent speculative run-up.
Low - Business model is not credit-dependent. Primary credit risk is counterparty exposure to government agencies with 90-180 day payment cycles, but these are typically backed by sovereign or multilateral funding. Strong 7.18 current ratio provides liquidity buffer for working capital needs.
momentum - The 516% one-year return and 150% six-month return with minimal fundamental improvement (5.6% revenue growth, deteriorating cash flow) indicates pure momentum/speculative positioning. Extreme valuation multiples and negative FCF yield make this unsuitable for value investors. No dividend yield eliminates income investors. Current holders are likely retail momentum traders or thematic ESG investors focused on sexual health access narrative rather than institutional fundamental buyers.
high - Recent 39% three-month move demonstrates extreme volatility. Small-cap emerging market stock with limited float and institutional ownership creates susceptibility to sharp reversals. Beta likely exceeds 1.5-2.0 relative to Indian equity indices.